Latest Market Data
Hang Seng Index
22,504.68
+385.27 (+1.74%)
HSCEI
8,231.04
+154.78 (+1.92%)
Hang Seng TECH Index
5,244.06
+156.64 (+3.08%)
Hang Seng HKEX Stock Connect China Enterprises Index
3,827.24
+50.94 (+1.35%)
MSCI China A 50 Connect Index
2,055.27
- (-)
HSI Volatility Index
27.40
+0.87 (+3.28%)
CSI 300 Index
3,770.57
-4.51 (-0.12%)
CES China120 Index
6,363.17
+70.36 (+1.12%)
USD/CNH Spot
7.2094
-0.0014 (-0.02%)
USD/INR Spot
84.4990
-0.0810 (-0.10%)
HKEX Bitcoin Reference Index
95,431.47
-463.39 (-0.48%)
HKEX Ether Reference Index
1,828.47
-12.62 (-0.69%)
CNH Gold Futures – Spot Price Index
-
- (-)
USD Gold Futures – Spot Price Index
-
- (-)
Refresh
Market Turnover
-






-
-
|
|
|
|
|
|
-
-
-
Loading

DUALITY BIOTHERAPEUTICS, INC. - B (9606)

DUALITYBIO-B (9606)

HK$215.600

+8.200 (+3.95%)

Prev. Close is the most recent non-zero closing value or settlement price.PREV. CLOSE
HK$207.400
Open price is the first traded price of the day. The opening price is reported after 09:20:00 HKT.OPEN
HK$207.400
TURNOVER
HK$46.41M
VOLUME
215.80K
MKT CAP
HK$18.42B
LOT SIZE
100
BID
HK$215.600
ASK
HK$215.800
EPS
-
P/E
-
DIV YIELD
-
INTRA-DAY 52W
High HK$219.600 HK$234.600
Low HK$202.400 HK$178.800
Information is available after the market opens and is delayed by at least 15 minutes.
Updated: 02 May 2025 16:08 HKT
  • 1 D
  • 1 M
  • 3 M
  • 6 M
  • YTD
  • 1 Y
  • 2 Y
  • 5 Y
  • 10 Y
1min
5min
15min
Hourly
Created with Highstock 6.2.00.000200.000205.000210.000215.000220.00004K8K10:0011:0012:0013:0014:0015:0016:00Prev. Close
207.400
All charts use the last traded price or closing price.

COMPANY PROFILE

Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares) 85,436,464 (as at 15 Apr 2025)
Industry Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Listing Date 15 Apr 2025
Financial Year Ends -
Chairman Zhu Zhongyuan
Principal Office 40/F
Dah Sing Financial Centre
248 Queen's Road East
Wanchai, Hong Kong
Place of Incorporation Cayman Islands
Listing Category Primary Listing

a. Updating time-lag
The number of issued shares / issued units presented is generally updated within 7 days after the Monthly Returns and Next Day Disclosure Returns published by the listed issuers on the HKEXnews website. Hence, the information presented here may not be the most up-to-date information submitted by the listed issuers as required under the Listing Rules.
b. Rights issues or bonus issues
The number of issued shares / issued units presented here will be adjusted with effect from the ex-date in the event of announced rights issues or announced bonus issues. In this case, both the number of issued shares / issued units before and after the adjustment will be presented.
c. Share splits or share consolidations
The number of issued shares / issued units presented here will be adjusted on the effective date in the event of share splits or share consolidations.
d. Conversion of convertible notes into shares
If the change of the number of issued shares / issued units is due to conversion of convertible bonds, the number of issued shares / issued units presented here may be updated based on the related company announcement.
Updated: 04 May 2025 08:02 HKT
* Company profile is provided by Refinitiv.

ENTITLEMENT

Date Announced Ex-Date Details Financial Year End Book Close Date Payment date may be indicative only.Payment Date
Updated:
Dividend details are sourced from Announcement Forms published on HKEXnews